Strong Q3 result: 10% organic growth
Chr. Hansen realizes strong organic revenue growth of 10% in the first nine months of 2016/17. Based on this we have narrowed our organic revenue expectations for 2016/17 to 9%-10% from previously 8-10%.
Chr. Hansen realizes strong organic revenue growth of 10% in the first nine months of 2016/17. Based on this we have narrowed our organic revenue expectations for 2016/17 to 9%-10% from previously 8-10%.
Chr. Hansen realizes strong organic revenue growth of 10% in the first half of 2016/17. With this solid performance in the first half year, we are well positioned to deliver on our ambitions for the year.
Chr. Hansen realizes strong organic growth of 12% in the financial year 2015/16, delivering at the upper end of our Nature’s no. 1™ growth ambitions.
Natural solutions that advance human health are in high demand and the expected growth for microbial solutions in this industry is 7-9%. Chr. Hansen is the world’s leading supplier of probiotics to dietary supplements, infant formula and dairy, and through the acquisition of the LGG® business, the company is now further strengthening its microbial platform across all three categories.
Based on the results for the first half of the year Chr. Hansen raises expectations for organic revenue growth for 2015-16 to 10-12% (previously 9-11%).
MÅ IKKE OFFENTLIGGØRES ELLER UDLEVERES HELT ELLER DELVIST, DIREKTE ELLER
INDIREKTE, I ELLER TIL USA, AUSTRALIEN, CANADA, JAPAN ELLER SYDAFRIKA.
Overallokeringsret udnyttet fuldt ud
Samlet størrelse på børsnotering og udbud af aktier forøget til DKK 5.521 mio.
Chr. Hansen Holding A/S (“Chr. Hansen”) offentliggør hermed, at Joint Global
Coordinators, Credit Suisse og J.P. Morgan (p
Selskabsmeddelelse nr.4/20103. juni 2010
Finanskalender for regnskabsåret 2009/2010
Delårsregnskab for de første 3 kvartaler 2009/2010: 1. juli 2010
Årsrapport for 2009/2010: 2. november 2010
Ordinær generalforsamling: 30. november 2010
selskabsmeddelelse nr.3/20103, juni 2010
MÅ IKKE OFFENTLIGGØRES ELLER UDLEVERES HELT ELLER DELVIST, DIREKTE ELLER
INDIREKTE, I ELLER TIL USA, AUSTRALIEN, CANADA, JAPAN ELLER SYDAFRIKA
Chr. Hansen fastsætter udbudskurs til DKK 90 pr. aktie i forbindelse med
selskabets børsnotering og udbud af aktier
Chr. Hansen Holding A/S (“Chr. Hansen”, eller “Selskabet”), der er en g
Chr. Hansen is a global, differentiated bioscience company that develops natural ingredient solutions for the food, nutritional, pharmaceutical and agricultural industries. At Chr. Hansen we are uniquely positioned to drive positive change through microbial solutions. We have worked for over 150 years to enable sustainable agriculture, better food and healthier living for more people around the world. Our microbial and fermentation technology platforms, including our broad and relevant collection of around 50,000 microbial strains, have game-changing potential. Matching customer needs and global trends we continue to unlock the power of good bacteria to respond to global challenges such as food waste, global health and the overuse of antibiotics and pesticides. As one of the world’s most sustainable companies, we touch the lives of more than 1 billion people every day. Driven by our legacy of innovation and curiosity to pioneer science, our purpose – To grow a better world. Naturally. – is at the heart of everything we do.
Boege Allé 10-12
DK-2970 Hoersholm
Denmark